Prevalence and Incidence of Neuromyelitis Optica Spectrum Disorder in Korea: Population Based Study

J Korean Med Sci. 2020 May 4;35(17):e115. doi: 10.3346/jkms.2020.35.e115.

Abstract

Background: Although neuromyelitis optica spectrum disorder (NMOSD) is known to be a rare disease, its prevalence and incidence have not yet been studied in Korea. We performed a population-based study to examine the prevalence and incidence of NMOSD in Korea using data from the Korean National Health Insurance (NHI) claims database.

Methods: Data from 2013 to 2017 were obtained, with a washout period set as 2013 and 2014. The prevalence and incidence of NMOSD in 2016 and 2017 were calculated using population census data. Subjects were divided into 5 groups at 15-year intervals, depending on the age at which the diagnostic code was entered. The relative risk (RR) for each age group was compared with the oldest (≥ 60 years) age group.

Results: The overall prevalence was estimated to be 3.36 and 3.56 per 100,000 individuals, with an incidence of 0.41 and 0.65 per 100,000 individuals-year in 2016 and 2017, respectively. The mean age was 43.08 (standard deviation, 14.56) years, and the ratio of male to females was 1:4.7. The incidence was higher in female individuals aged between 30 and 59 years (RR, 2.8-3.05; P < 0.05).

Conclusion: Nationwide prevalence of NMOSD in Korea was 3.36 and 3.56/100,000 and its incidence was 0.41 and 0.65/100,000-year in 2016 and 2017 respectively.

Keywords: Incidence; NMOSD; Neuromyelitis Optica Spectrum Disorder; Prevalence.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Azathioprine / therapeutic use
  • Child
  • Databases, Factual
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Neuromyelitis Optica / diagnosis*
  • Neuromyelitis Optica / drug therapy
  • Neuromyelitis Optica / epidemiology
  • Prevalence
  • Republic of Korea / epidemiology
  • Risk Factors
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Azathioprine